Nanjing Vcare Assists Hualon Pharmaceutical in Passing the Conformity Evaluation for Omeprazole Sodium and Pantoprazole Sodium

2021-11-19

Recently, Nanjing Vcare has been making headlines with good news. The "Omeprazole Sodium for Injection (40mg)" and "Pantoprazole Sodium for Injection (40mg)" products, which were entrusted to Nanjing Vcare by its partner Hainan Hualon Pharmaceutical Co., Ltd., passed the national uniformity evaluation in September and November respectively. Nanjing Vcare was responsible for the pharmacological uniformity evaluation research for these two projects, effectively saving development time and costs for the client. The professional capabilities and "full-chain, full-life cycle" service philosophy of Nanjing Vcare were once again fully validated in the implementation of these two projects.

 

Injection of omeprazole sodium and injection of pantoprazole sodium are mainly used for bleeding of peptic ulcer, ulcer bleeding after anastomosis, acute gastric mucosal injury caused by stress state, acute gastric mucosal injury caused by non-steroidal anti-inflammatory drugs, prevention of upper gastrointestinal bleeding in severe diseases such as cerebral hemorrhage and serious trauma, and postoperative upper gastrointestinal bleeding after gastrointestinal surgery. Injection of omeprazole sodium and injection of pantoprazole sodium have passed the national consistency evaluation, which has effectively assisted Huanglong Pharmaceutical in enriching and enhancing its sales advantage of injectable products line and increasing market competitiveness.

Prev

Nanjing Vcare CDMO Business Technology Center was Established and Put Into Operation

Next

Nanjing Vcare Assists Nanjing Chiatai Tianqing in Obtaining Lenvatinib Production License